260 related articles for article (PubMed ID: 38344201)
41. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Réda M; Fouquier A; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Coudert B; Bertaut A; Ladoire S
Breast; 2023 Apr; 68():149-156. PubMed ID: 36773403
[TBL] [Abstract][Full Text] [Related]
42. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
[TBL] [Abstract][Full Text] [Related]
43. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
44. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
45. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
[TBL] [Abstract][Full Text] [Related]
46. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
47. Benzimidazole carbamate induces cytotoxicity in breast cancer cells via two distinct cell death mechanisms.
Graff BT; Palanivel C; Jenkins CB; Baranowska-Kortylewicz J; Yan Y
Cell Death Discov; 2023 May; 9(1):162. PubMed ID: 37179350
[TBL] [Abstract][Full Text] [Related]
48. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
[TBL] [Abstract][Full Text] [Related]
50. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.
You S; Gong C; Li Y; Xie Y; Li Y; Zhao Y; Wang B
Front Endocrinol (Lausanne); 2023; 14():1270453. PubMed ID: 37881502
[TBL] [Abstract][Full Text] [Related]
53. RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
Chen J; Wang M; Qi X; Long H; Qi N; Wu L; Ke M; Shao S; Li P; Chen Y; Wang W; Zhu S; Qi X; Li G
Clin Genitourin Cancer; 2024 Jun; 22(3):102093. PubMed ID: 38762350
[TBL] [Abstract][Full Text] [Related]
54. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
55.
Fusco N; Malapelle U; Fassan M; Marchiò C; Buglioni S; Zupo S; Criscitiello C; Vigneri P; Dei Tos AP; Maiorano E; Viale G
Front Oncol; 2021; 11():644737. PubMed ID: 33842357
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
57. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
[TBL] [Abstract][Full Text] [Related]
59. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
Tan X; Wang Y; Wu Z; Zhou Q; Tang Y; Liu Z; Yuan G; Luo S; Zou Y; Guo S; Han N; Yao K
Eur J Cancer; 2023 Nov; 194():113360. PubMed ID: 37862796
[TBL] [Abstract][Full Text] [Related]
60. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Anderson EJ; Mollon LE; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Int J Breast Cancer; 2020; 2020():3759179. PubMed ID: 32637176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
